Elizabeth Pomfret
Concepts (518)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 133 | 2026 | 823 | 17.980 |
Why?
| | Living Donors | 78 | 2025 | 280 | 13.410 |
Why?
| | Tissue and Organ Procurement | 43 | 2026 | 346 | 8.050 |
Why?
| | Tissue Donors | 19 | 2025 | 424 | 3.460 |
Why?
| | Hepatectomy | 26 | 2025 | 273 | 3.280 |
Why?
| | Donor Selection | 16 | 2024 | 79 | 3.050 |
Why?
| | End Stage Liver Disease | 14 | 2025 | 94 | 2.700 |
Why?
| | Organ Transplantation | 18 | 2026 | 247 | 2.570 |
Why?
| | Kidney Transplantation | 16 | 2025 | 704 | 2.480 |
Why?
| | Perfusion | 9 | 2026 | 250 | 2.140 |
Why?
| | Patient Selection | 15 | 2025 | 719 | 1.890 |
Why?
| | Liver | 42 | 2023 | 1887 | 1.890 |
Why?
| | Carcinoma, Hepatocellular | 9 | 2023 | 370 | 1.780 |
Why?
| | Liver Neoplasms | 11 | 2025 | 780 | 1.630 |
Why?
| | Postoperative Complications | 28 | 2025 | 2919 | 1.490 |
Why?
| | Resource Allocation | 5 | 2025 | 53 | 1.420 |
Why?
| | Waiting Lists | 17 | 2025 | 263 | 1.380 |
Why?
| | Liver Cirrhosis | 9 | 2020 | 288 | 1.300 |
Why?
| | Tissue and Organ Harvesting | 10 | 2024 | 73 | 1.270 |
Why?
| | Graft Survival | 19 | 2025 | 526 | 1.240 |
Why?
| | Organ Preservation | 7 | 2026 | 130 | 1.110 |
Why?
| | Humans | 189 | 2026 | 144759 | 1.080 |
Why?
| | United States | 46 | 2026 | 15966 | 0.940 |
Why?
| | Laparoscopy | 3 | 2023 | 475 | 0.920 |
Why?
| | Hepatitis C, Chronic | 5 | 2022 | 152 | 0.900 |
Why?
| | Fatty Liver | 6 | 2023 | 251 | 0.900 |
Why?
| | Informed Consent | 3 | 2024 | 198 | 0.890 |
Why?
| | Lung Transplantation | 3 | 2025 | 338 | 0.870 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 57 | 0.860 |
Why?
| | Liver Diseases | 5 | 2023 | 304 | 0.810 |
Why?
| | Consensus | 9 | 2025 | 488 | 0.810 |
Why?
| | Immunotoxins | 4 | 2025 | 55 | 0.760 |
Why?
| | Graft Rejection | 13 | 2020 | 540 | 0.730 |
Why?
| | Transplant Recipients | 8 | 2025 | 180 | 0.720 |
Why?
| | Adult | 80 | 2026 | 40449 | 0.690 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 182 | 0.680 |
Why?
| | Surgeons | 3 | 2025 | 339 | 0.670 |
Why?
| | Liver Failure | 7 | 2016 | 83 | 0.670 |
Why?
| | Middle Aged | 74 | 2026 | 35875 | 0.650 |
Why?
| | Frailty | 1 | 2023 | 198 | 0.600 |
Why?
| | Male | 92 | 2026 | 72315 | 0.600 |
Why?
| | Female | 91 | 2026 | 78271 | 0.600 |
Why?
| | Societies, Medical | 5 | 2026 | 887 | 0.590 |
Why?
| | Portal Vein | 4 | 2017 | 114 | 0.580 |
Why?
| | Diphtheria Toxin | 4 | 2025 | 65 | 0.580 |
Why?
| | Periodicals as Topic | 2 | 2026 | 203 | 0.570 |
Why?
| | Treatment Outcome | 36 | 2025 | 11679 | 0.560 |
Why?
| | Survival Rate | 15 | 2025 | 2089 | 0.530 |
Why?
| | Immunosuppressive Agents | 6 | 2018 | 846 | 0.530 |
Why?
| | Hepatic Veins | 5 | 2016 | 32 | 0.500 |
Why?
| | Thrombelastography | 6 | 2023 | 178 | 0.490 |
Why?
| | Kidney Failure, Chronic | 4 | 2025 | 598 | 0.480 |
Why?
| | Healthcare Disparities | 6 | 2025 | 727 | 0.480 |
Why?
| | Retrospective Studies | 35 | 2026 | 17066 | 0.470 |
Why?
| | Social Determinants of Health | 3 | 2026 | 301 | 0.460 |
Why?
| | Antiviral Agents | 4 | 2022 | 767 | 0.460 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 266 | 0.460 |
Why?
| | Blood Coagulation Disorders | 4 | 2022 | 189 | 0.450 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2017 | 28 | 0.450 |
Why?
| | Transplantation, Homologous | 8 | 2020 | 415 | 0.450 |
Why?
| | Venous Thrombosis | 1 | 2017 | 194 | 0.450 |
Why?
| | Biopsy | 9 | 2020 | 1075 | 0.450 |
Why?
| | Sirolimus | 1 | 2016 | 281 | 0.410 |
Why?
| | Interleukin-2 | 4 | 2024 | 437 | 0.410 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2925 | 0.400 |
Why?
| | Biliary Tract Diseases | 2 | 2010 | 33 | 0.390 |
Why?
| | Tissue Plasminogen Activator | 4 | 2023 | 244 | 0.390 |
Why?
| | Kidney | 6 | 2023 | 1495 | 0.390 |
Why?
| | Risk Factors | 19 | 2025 | 10779 | 0.390 |
Why?
| | Hepacivirus | 7 | 2022 | 243 | 0.380 |
Why?
| | Registries | 7 | 2025 | 2385 | 0.380 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 1137 | 0.360 |
Why?
| | Follow-Up Studies | 13 | 2025 | 5408 | 0.360 |
Why?
| | Tomography, X-Ray Computed | 9 | 2017 | 2730 | 0.360 |
Why?
| | Time Factors | 19 | 2026 | 7173 | 0.350 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 121 | 0.350 |
Why?
| | Hepatitis C | 5 | 2022 | 254 | 0.350 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 45 | 0.340 |
Why?
| | Prognosis | 11 | 2025 | 4282 | 0.340 |
Why?
| | Liver Regeneration | 4 | 2003 | 46 | 0.330 |
Why?
| | Allografts | 3 | 2023 | 150 | 0.320 |
Why?
| | Resuscitation | 2 | 2024 | 302 | 0.300 |
Why?
| | Biliary Tract | 1 | 2008 | 14 | 0.290 |
Why?
| | Directed Tissue Donation | 1 | 2008 | 5 | 0.290 |
Why?
| | Patient Safety | 1 | 2012 | 347 | 0.290 |
Why?
| | Blood Coagulation | 5 | 2023 | 268 | 0.290 |
Why?
| | Bioethical Issues | 1 | 2008 | 8 | 0.290 |
Why?
| | Quality of Life | 8 | 2025 | 3185 | 0.290 |
Why?
| | Aged | 33 | 2025 | 25913 | 0.280 |
Why?
| | Interpersonal Relations | 1 | 2011 | 400 | 0.280 |
Why?
| | Vascular Surgical Procedures | 1 | 2011 | 339 | 0.270 |
Why?
| | Terminology as Topic | 3 | 2024 | 255 | 0.270 |
Why?
| | Adolescent | 23 | 2024 | 22428 | 0.270 |
Why?
| | Transplants | 2 | 2022 | 39 | 0.260 |
Why?
| | Software | 2 | 2012 | 690 | 0.260 |
Why?
| | Tacrolimus | 3 | 2020 | 196 | 0.250 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2006 | 24 | 0.250 |
Why?
| | Fibrinolysis | 3 | 2023 | 162 | 0.240 |
Why?
| | Practice Guidelines as Topic | 6 | 2025 | 1560 | 0.240 |
Why?
| | Young Adult | 12 | 2024 | 14105 | 0.240 |
Why?
| | Transplantation Immunology | 1 | 2006 | 29 | 0.240 |
Why?
| | Warm Ischemia | 1 | 2025 | 18 | 0.230 |
Why?
| | Insurance, Life | 1 | 2005 | 2 | 0.230 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2194 | 0.230 |
Why?
| | Risk Assessment | 10 | 2025 | 3671 | 0.220 |
Why?
| | International Cooperation | 2 | 2016 | 198 | 0.220 |
Why?
| | Flank Pain | 1 | 2024 | 9 | 0.220 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.220 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 26 | 0.220 |
Why?
| | Renal Nutcracker Syndrome | 1 | 2024 | 8 | 0.220 |
Why?
| | Intestines | 2 | 2007 | 358 | 0.210 |
Why?
| | Health Care Rationing | 3 | 2013 | 59 | 0.210 |
Why?
| | Skin Neoplasms | 2 | 2023 | 847 | 0.210 |
Why?
| | Solitary Kidney | 1 | 2023 | 2 | 0.210 |
Why?
| | Decision Making | 1 | 2011 | 975 | 0.210 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 585 | 0.200 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 290 | 0.200 |
Why?
| | Critical Care | 4 | 2024 | 695 | 0.200 |
Why?
| | Sezary Syndrome | 1 | 2023 | 45 | 0.200 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 62 | 0.190 |
Why?
| | Congresses as Topic | 1 | 2024 | 221 | 0.190 |
Why?
| | Body Mass Index | 2 | 2024 | 2438 | 0.190 |
Why?
| | Incidence | 7 | 2025 | 2879 | 0.190 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 35 | 0.190 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2011 | 1414 | 0.190 |
Why?
| | Body Temperature | 1 | 2023 | 229 | 0.180 |
Why?
| | Length of Stay | 3 | 2023 | 1337 | 0.180 |
Why?
| | Operative Time | 1 | 2023 | 175 | 0.180 |
Why?
| | Death | 3 | 2023 | 130 | 0.180 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2023 | 76 | 0.180 |
Why?
| | Bile Ducts | 2 | 2022 | 67 | 0.180 |
Why?
| | Thrombosis | 3 | 2022 | 393 | 0.180 |
Why?
| | Sodium | 1 | 2022 | 197 | 0.170 |
Why?
| | Evidence-Based Medicine | 3 | 2016 | 732 | 0.170 |
Why?
| | Massachusetts | 2 | 2012 | 180 | 0.170 |
Why?
| | Case-Control Studies | 5 | 2023 | 3604 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 2 | 2020 | 129 | 0.170 |
Why?
| | Cause of Death | 3 | 2025 | 471 | 0.170 |
Why?
| | Cholangitis, Sclerosing | 3 | 2009 | 60 | 0.170 |
Why?
| | Sex Factors | 3 | 2024 | 2112 | 0.170 |
Why?
| | Prothrombin Time | 1 | 2000 | 33 | 0.170 |
Why?
| | Recurrence | 10 | 2011 | 1135 | 0.160 |
Why?
| | Physicians | 2 | 2010 | 939 | 0.160 |
Why?
| | Predictive Value of Tests | 5 | 2020 | 2115 | 0.160 |
Why?
| | Educational Status | 3 | 2022 | 467 | 0.160 |
Why?
| | Bupivacaine | 1 | 2000 | 38 | 0.160 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 171 | 0.160 |
Why?
| | Reperfusion | 1 | 2020 | 54 | 0.160 |
Why?
| | Prospective Studies | 11 | 2020 | 7990 | 0.160 |
Why?
| | Diagnostic Imaging | 2 | 2013 | 338 | 0.160 |
Why?
| | Analgesia, Epidural | 1 | 2000 | 38 | 0.160 |
Why?
| | Temperature | 1 | 2023 | 679 | 0.160 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2020 | 9 | 0.160 |
Why?
| | Thymidine Phosphorylase | 1 | 2020 | 14 | 0.160 |
Why?
| | Costs and Cost Analysis | 3 | 2024 | 219 | 0.160 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 51 | 0.160 |
Why?
| | Cholestasis | 1 | 2023 | 219 | 0.160 |
Why?
| | Anesthetics, Local | 1 | 2000 | 100 | 0.150 |
Why?
| | Policy | 1 | 2021 | 146 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1095 | 0.150 |
Why?
| | Choline | 4 | 1989 | 136 | 0.150 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 103 | 0.150 |
Why?
| | Nephrectomy | 1 | 2020 | 158 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 316 | 0.150 |
Why?
| | Disease Progression | 5 | 2025 | 2847 | 0.150 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 291 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2012 | 3409 | 0.150 |
Why?
| | Viremia | 1 | 2020 | 158 | 0.140 |
Why?
| | Medicare | 1 | 2024 | 886 | 0.140 |
Why?
| | Biliary Atresia | 1 | 2020 | 158 | 0.140 |
Why?
| | Risk | 3 | 2016 | 911 | 0.140 |
Why?
| | Catheterization | 2 | 2023 | 183 | 0.140 |
Why?
| | Amyloid Neuropathies | 1 | 1998 | 1 | 0.140 |
Why?
| | Age Distribution | 2 | 2011 | 403 | 0.140 |
Why?
| | Gastric Bypass | 1 | 2020 | 125 | 0.140 |
Why?
| | Mice, SCID | 3 | 2025 | 369 | 0.140 |
Why?
| | Cohort Studies | 9 | 2025 | 5960 | 0.140 |
Why?
| | Bile Duct Diseases | 1 | 2017 | 13 | 0.130 |
Why?
| | Telomerase | 1 | 2020 | 248 | 0.130 |
Why?
| | Phlebography | 1 | 2017 | 39 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 558 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2025 | 845 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2026 | 1098 | 0.130 |
Why?
| | Obesity, Morbid | 2 | 2020 | 281 | 0.130 |
Why?
| | Prevalence | 3 | 2023 | 2834 | 0.130 |
Why?
| | Premature Birth | 1 | 2021 | 380 | 0.130 |
Why?
| | Incidental Findings | 1 | 2017 | 80 | 0.130 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 102 | 0.130 |
Why?
| | North America | 3 | 2025 | 310 | 0.130 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 126 | 0.130 |
Why?
| | Drug Overdose | 1 | 2021 | 370 | 0.120 |
Why?
| | Reoperation | 6 | 2017 | 630 | 0.120 |
Why?
| | Bariatric Surgery | 1 | 2020 | 242 | 0.120 |
Why?
| | Child | 8 | 2022 | 22633 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 6048 | 0.120 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 1519 | 0.120 |
Why?
| | Communicable Diseases | 1 | 2017 | 163 | 0.110 |
Why?
| | Postoperative Period | 4 | 2020 | 354 | 0.110 |
Why?
| | Morbidity | 2 | 2013 | 323 | 0.110 |
Why?
| | Iron | 1 | 2017 | 359 | 0.110 |
Why?
| | Perioperative Care | 1 | 2017 | 231 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 288 | 0.110 |
Why?
| | Monitoring, Physiologic | 2 | 1994 | 289 | 0.110 |
Why?
| | Mycophenolic Acid | 2 | 2014 | 120 | 0.110 |
Why?
| | Cadaver | 3 | 2015 | 304 | 0.110 |
Why?
| | Transplantation | 2 | 2024 | 33 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 928 | 0.110 |
Why?
| | Antilymphocyte Serum | 1 | 2014 | 61 | 0.110 |
Why?
| | Organ Size | 2 | 2012 | 463 | 0.110 |
Why?
| | Parents | 2 | 2020 | 1403 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 919 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1720 | 0.100 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 89 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 741 | 0.100 |
Why?
| | Withholding Treatment | 1 | 2014 | 80 | 0.100 |
Why?
| | Comorbidity | 1 | 2019 | 1658 | 0.100 |
Why?
| | Choline Deficiency | 3 | 1991 | 10 | 0.100 |
Why?
| | Steroids | 1 | 2014 | 160 | 0.100 |
Why?
| | Splenorenal Shunt, Surgical | 2 | 2006 | 3 | 0.100 |
Why?
| | Mitochondria | 1 | 2020 | 984 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 322 | 0.100 |
Why?
| | Data Collection | 2 | 2013 | 633 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 600 | 0.100 |
Why?
| | Physician Executives | 1 | 2013 | 27 | 0.100 |
Why?
| | Thoracic Injuries | 1 | 1993 | 72 | 0.090 |
Why?
| | Receptors, CCR4 | 2 | 2024 | 23 | 0.090 |
Why?
| | Anticoagulants | 1 | 2017 | 722 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2015 | 465 | 0.090 |
Why?
| | Catheterization, Central Venous | 1 | 1994 | 122 | 0.090 |
Why?
| | Therapeutic Equipoise | 1 | 2011 | 2 | 0.090 |
Why?
| | Liver Function Tests | 2 | 2020 | 106 | 0.090 |
Why?
| | Personnel Selection | 1 | 2013 | 93 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 610 | 0.080 |
Why?
| | Religion | 1 | 2011 | 65 | 0.080 |
Why?
| | Mental Health | 1 | 2018 | 790 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2015 | 353 | 0.080 |
Why?
| | Anastomosis, Surgical | 1 | 2011 | 157 | 0.080 |
Why?
| | Mice | 6 | 2025 | 18339 | 0.080 |
Why?
| | Family Relations | 1 | 2011 | 88 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2011 | 965 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3540 | 0.080 |
Why?
| | Health Status Indicators | 1 | 2011 | 166 | 0.080 |
Why?
| | Hepatitis, Autoimmune | 4 | 2006 | 13 | 0.080 |
Why?
| | Observer Variation | 1 | 2011 | 355 | 0.080 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 26 | 0.080 |
Why?
| | Animals | 14 | 2025 | 38058 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 24 | 0.080 |
Why?
| | Anesthesiology | 1 | 2013 | 175 | 0.080 |
Why?
| | Wounds, Nonpenetrating | 1 | 1993 | 316 | 0.080 |
Why?
| | Hypertension, Portal | 1 | 2010 | 66 | 0.080 |
Why?
| | Specialties, Surgical | 1 | 2011 | 82 | 0.080 |
Why?
| | Constriction, Pathologic | 2 | 2023 | 248 | 0.080 |
Why?
| | Obesity | 4 | 2024 | 3077 | 0.070 |
Why?
| | Linear Models | 1 | 2011 | 854 | 0.070 |
Why?
| | S-Adenosylmethionine | 1 | 1989 | 59 | 0.070 |
Why?
| | Critical Illness | 1 | 2015 | 891 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4089 | 0.070 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2009 | 62 | 0.070 |
Why?
| | Rats, Inbred Strains | 7 | 1991 | 321 | 0.070 |
Why?
| | Models, Biological | 2 | 2006 | 1821 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1325 | 0.070 |
Why?
| | Life Expectancy | 1 | 2009 | 72 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 478 | 0.070 |
Why?
| | Methionine | 1 | 1989 | 162 | 0.070 |
Why?
| | Blood Transfusion | 2 | 2025 | 405 | 0.070 |
Why?
| | Ventilator Weaning | 1 | 2008 | 39 | 0.070 |
Why?
| | Brain Death | 2 | 2024 | 60 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2010 | 267 | 0.070 |
Why?
| | Lithium | 1 | 1988 | 42 | 0.070 |
Why?
| | Rats | 8 | 2024 | 5597 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 1994 | 1134 | 0.070 |
Why?
| | Databases, Factual | 2 | 2025 | 1486 | 0.070 |
Why?
| | Documentation | 2 | 2024 | 198 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 675 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2011 | 893 | 0.060 |
Why?
| | Hypotension | 1 | 2008 | 126 | 0.060 |
Why?
| | General Surgery | 1 | 2010 | 207 | 0.060 |
Why?
| | Prealbumin | 1 | 2006 | 36 | 0.060 |
Why?
| | Abdomen | 2 | 2024 | 141 | 0.060 |
Why?
| | Heart Failure | 1 | 2020 | 2323 | 0.060 |
Why?
| | Parenteral Nutrition, Total | 2 | 2003 | 30 | 0.060 |
Why?
| | Survival Analysis | 4 | 2015 | 1382 | 0.060 |
Why?
| | Demography | 1 | 2007 | 288 | 0.060 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 36 | 0.060 |
Why?
| | Cold Ischemia | 1 | 2026 | 40 | 0.060 |
Why?
| | Safety | 1 | 2008 | 356 | 0.060 |
Why?
| | Neoplasm Staging | 1 | 2009 | 1462 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 985 | 0.060 |
Why?
| | History, 21st Century | 1 | 2026 | 219 | 0.060 |
Why?
| | History, 20th Century | 1 | 2026 | 325 | 0.050 |
Why?
| | Pain | 2 | 2022 | 779 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 136 | 0.050 |
Why?
| | Renal Veins | 1 | 2024 | 18 | 0.050 |
Why?
| | Xanthomatosis | 1 | 2004 | 8 | 0.050 |
Why?
| | Canada | 1 | 2025 | 428 | 0.050 |
Why?
| | Algorithms | 2 | 2011 | 1837 | 0.050 |
Why?
| | Swine, Miniature | 1 | 2024 | 89 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1356 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2025 | 769 | 0.050 |
Why?
| | Employment | 1 | 2005 | 188 | 0.050 |
Why?
| | Salvage Therapy | 1 | 2024 | 162 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 614 | 0.050 |
Why?
| | Granuloma | 1 | 2004 | 96 | 0.050 |
Why?
| | Bilirubin | 1 | 2023 | 97 | 0.050 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2003 | 15 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 10 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 118 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2014 | 1982 | 0.050 |
Why?
| | Shock | 1 | 2024 | 108 | 0.050 |
Why?
| | Laboratories | 1 | 2023 | 109 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 71 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 380 | 0.050 |
Why?
| | Platelet Count | 1 | 2022 | 96 | 0.050 |
Why?
| | Research | 1 | 2006 | 431 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 84 | 0.050 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2002 | 19 | 0.050 |
Why?
| | Depression | 2 | 2018 | 1558 | 0.050 |
Why?
| | Information Dissemination | 1 | 2024 | 223 | 0.050 |
Why?
| | Infant | 3 | 2021 | 10034 | 0.040 |
Why?
| | Pain Measurement | 1 | 2024 | 552 | 0.040 |
Why?
| | Mentors | 1 | 2024 | 219 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2009 | 2050 | 0.040 |
Why?
| | Platelet Transfusion | 1 | 2022 | 80 | 0.040 |
Why?
| | Patients | 1 | 2023 | 180 | 0.040 |
Why?
| | Propensity Score | 1 | 2023 | 367 | 0.040 |
Why?
| | RNA, Viral | 3 | 2013 | 688 | 0.040 |
Why?
| | Hypophosphatemia | 1 | 2001 | 17 | 0.040 |
Why?
| | Creatinine | 1 | 2023 | 506 | 0.040 |
Why?
| | Swine | 1 | 2024 | 833 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 573 | 0.040 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 72 | 0.040 |
Why?
| | Family | 1 | 2005 | 679 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2020 | 121 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 56 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 90 | 0.040 |
Why?
| | Thymidine | 1 | 2020 | 60 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 341 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 91 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 157 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 80 | 0.040 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 29 | 0.040 |
Why?
| | Preoperative Care | 1 | 2022 | 379 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 2020 | 220 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 307 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6429 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 627 | 0.040 |
Why?
| | Hemangioma, Cavernous | 1 | 1999 | 13 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 386 | 0.040 |
Why?
| | HLA Antigens | 1 | 2020 | 225 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2001 | 780 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2023 | 462 | 0.040 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 133 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 400 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3333 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1980 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 323 | 0.030 |
Why?
| | Gastrectomy | 1 | 2020 | 161 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 732 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 476 | 0.030 |
Why?
| | Anatomic Variation | 1 | 2017 | 4 | 0.030 |
Why?
| | Hepcidins | 1 | 2017 | 22 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2005 | 2947 | 0.030 |
Why?
| | Pancreas Transplantation | 2 | 2009 | 69 | 0.030 |
Why?
| | Mammary Glands, Animal | 2 | 1988 | 128 | 0.030 |
Why?
| | Nervous System | 1 | 1998 | 70 | 0.030 |
Why?
| | Pilot Projects | 2 | 2014 | 1886 | 0.030 |
Why?
| | Boston | 1 | 2017 | 92 | 0.030 |
Why?
| | Ferritins | 1 | 2017 | 69 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 529 | 0.030 |
Why?
| | Phosphatidylcholines | 2 | 1988 | 131 | 0.030 |
Why?
| | Hepatic Artery | 3 | 2003 | 53 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1370 | 0.030 |
Why?
| | Cardiovascular System | 1 | 1998 | 137 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 201 | 0.030 |
Why?
| | Sepsis | 1 | 2022 | 640 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2020 | 1173 | 0.030 |
Why?
| | Acute-On-Chronic Liver Failure | 1 | 2015 | 5 | 0.030 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 25 | 0.030 |
Why?
| | Communication | 1 | 2022 | 965 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1143 | 0.030 |
Why?
| | Hepatorenal Syndrome | 1 | 2015 | 15 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 366 | 0.030 |
Why?
| | Cross Infection | 1 | 1998 | 262 | 0.030 |
Why?
| | Contraindications | 2 | 2006 | 91 | 0.030 |
Why?
| | Benchmarking | 1 | 2016 | 188 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 84 | 0.030 |
Why?
| | Contrast Media | 2 | 2013 | 488 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 947 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 521 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 371 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 969 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 147 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 268 | 0.030 |
Why?
| | Genotype | 2 | 2013 | 1833 | 0.030 |
Why?
| | Mesothelioma | 2 | 1985 | 48 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 675 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 2011 | 8265 | 0.030 |
Why?
| | Peritoneal Neoplasms | 2 | 1985 | 103 | 0.020 |
Why?
| | Equipment Failure | 1 | 1994 | 115 | 0.020 |
Why?
| | Constitution and Bylaws | 1 | 2013 | 1 | 0.020 |
Why?
| | Decision Trees | 1 | 1993 | 81 | 0.020 |
Why?
| | Rabbits | 1 | 2014 | 648 | 0.020 |
Why?
| | Hospitals, Low-Volume | 1 | 2013 | 25 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 72 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1694 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1991 | 594 | 0.020 |
Why?
| | Hospitals, High-Volume | 1 | 2013 | 49 | 0.020 |
Why?
| | Pediatrics | 1 | 2001 | 1114 | 0.020 |
Why?
| | Viral Envelope Proteins | 1 | 2013 | 98 | 0.020 |
Why?
| | Certification | 1 | 2013 | 119 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1539 | 0.020 |
Why?
| | Clinical Protocols | 1 | 1993 | 282 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 634 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 539 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 817 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 578 | 0.020 |
Why?
| | Patient Readmission | 1 | 2016 | 758 | 0.020 |
Why?
| | Education | 1 | 2011 | 104 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1109 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2027 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1054 | 0.020 |
Why?
| | Biological Transport | 2 | 1988 | 417 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 1993 | 842 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 1135 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1993 | 326 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 1993 | 340 | 0.020 |
Why?
| | Pregnancy | 2 | 2021 | 7190 | 0.020 |
Why?
| | Methotrexate | 1 | 1991 | 240 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2004 | 1489 | 0.020 |
Why?
| | Ursodeoxycholic Acid | 1 | 2009 | 17 | 0.020 |
Why?
| | Cholagogues and Choleretics | 1 | 2009 | 5 | 0.020 |
Why?
| | Folic Acid | 1 | 1991 | 199 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2010 | 87 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1989 | 131 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 1998 | 1098 | 0.020 |
Why?
| | Workload | 1 | 2011 | 170 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1047 | 0.020 |
Why?
| | Phosphatidylethanolamines | 1 | 1988 | 76 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 408 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 589 | 0.020 |
Why?
| | Life Style | 1 | 2011 | 479 | 0.020 |
Why?
| | Methyltransferases | 1 | 1988 | 74 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 221 | 0.020 |
Why?
| | Health Policy | 1 | 2011 | 400 | 0.020 |
Why?
| | Breast | 1 | 1988 | 158 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 2029 | 0.020 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 557 | 0.020 |
Why?
| | Gastroenterology | 1 | 2010 | 189 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 582 | 0.020 |
Why?
| | Betaine | 1 | 1988 | 65 | 0.020 |
Why?
| | Selenium Compounds | 1 | 1987 | 18 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2011 | 547 | 0.020 |
Why?
| | Blood Glucose | 1 | 1998 | 2327 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 865 | 0.020 |
Why?
| | Selenium | 1 | 1987 | 49 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3863 | 0.020 |
Why?
| | Needs Assessment | 1 | 2010 | 404 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 1987 | 112 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11787 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4271 | 0.010 |
Why?
| | Fellowships and Scholarships | 1 | 2010 | 357 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 474 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 2008 | 320 | 0.010 |
Why?
| | Survivors | 1 | 2009 | 520 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 8 | 0.010 |
Why?
| | Clinical Competence | 1 | 2013 | 1244 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5868 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 166 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1984 | 173 | 0.010 |
Why?
| | Tissue Adhesions | 1 | 2004 | 34 | 0.010 |
Why?
| | Lacerations | 1 | 2004 | 40 | 0.010 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2004 | 97 | 0.010 |
Why?
| | Curriculum | 1 | 2010 | 1059 | 0.010 |
Why?
| | Angiography | 1 | 2003 | 208 | 0.010 |
Why?
| | Intraoperative Complications | 1 | 2004 | 155 | 0.010 |
Why?
| | Hepatitis C Antibodies | 1 | 2002 | 11 | 0.010 |
Why?
| | Internship and Residency | 1 | 2013 | 1257 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 1988 | 676 | 0.010 |
Why?
| | Inflammation | 1 | 1993 | 2878 | 0.010 |
Why?
| | Azathioprine | 1 | 2001 | 49 | 0.010 |
Why?
| | Erythrocytes | 1 | 1988 | 757 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1769 | 0.010 |
Why?
| | Spleen | 1 | 2003 | 508 | 0.010 |
Why?
| | Ischemia | 1 | 2003 | 421 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2001 | 254 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2003 | 365 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2003 | 463 | 0.010 |
Why?
| | APACHE | 1 | 1998 | 66 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2001 | 583 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 222 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 270 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1985 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1983 | 1953 | 0.010 |
Why?
| | Combined Modality Therapy | 2 | 1985 | 1266 | 0.010 |
Why?
| | Pteroylpolyglutamic Acids | 1 | 1991 | 1 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1984 | 2637 | 0.010 |
Why?
| | Tetrahydrofolates | 1 | 1991 | 16 | 0.010 |
Why?
| | Phosphatidylethanolamine N-Methyltransferase | 1 | 1988 | 8 | 0.000 |
Why?
| | Hemicholinium 3 | 1 | 1988 | 2 | 0.000 |
Why?
| | Dinitrophenols | 1 | 1988 | 7 | 0.000 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 9 | 0.000 |
Why?
| | Ouabain | 1 | 1988 | 19 | 0.000 |
Why?
| | Osmolar Concentration | 1 | 1988 | 167 | 0.000 |
Why?
| | Methylation | 1 | 1988 | 242 | 0.000 |
Why?
| | Selenium Radioisotopes | 1 | 1987 | 2 | 0.000 |
Why?
| | Selenious Acid | 1 | 1987 | 3 | 0.000 |
Why?
| | Selenomethionine | 1 | 1987 | 4 | 0.000 |
Why?
| | Milk | 1 | 1988 | 119 | 0.000 |
Why?
| | Lactation | 1 | 1988 | 192 | 0.000 |
Why?
| | Epithelium | 1 | 1988 | 314 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1988 | 1047 | 0.000 |
Why?
| | Drug Evaluation | 1 | 1984 | 79 | 0.000 |
Why?
| | Kinetics | 1 | 1988 | 1627 | 0.000 |
Why?
| | Asbestos | 1 | 1983 | 35 | 0.000 |
Why?
| | Laparotomy | 1 | 1983 | 112 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1988 | 1125 | 0.000 |
Why?
| | Palliative Care | 1 | 1985 | 1002 | 0.000 |
Why?
|
|
Pomfret's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|